RRA
RIGL icon

Round Rock Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Round Rock Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,754
Closed -$237K – 340
2026
Q1 		$237K Buy
8,754
+9
+0.1% +$302 0.04% 291
2025
Q4 		$375K Buy
+8,745
New +$330K 0.06% 243

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Round Rock Advisors's RIGL Position: Q2 2026 in Review

Round Rock Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 8,754 shares — an estimated $237K sold.

Round Rock Advisors first reported a position in RIGL in Q4 2025 and held it in 2 quarters. The position peaked at $375K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Round Rock Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Round Rock Advisors sold 8,754 Rigel Pharmaceuticals shares in Q2 2026, an estimated $237K.
  • Round Rock Advisors first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Round Rock Advisors's Rigel Pharmaceuticals position peaked at $375K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.